A rational, triple-drug, fixed-dose combination (FDC) antihypertensive therapy designed for Indian patients with moderate to severe hypertension not adequately controlled with dual therapy. It combines an Angiotensin II Receptor Blocker (ARB), a unique dual L/N-type Calcium Channel Blocker (CCB), and a long-acting thiazide-like diuretic, offering synergistic blood pressure reduction, improved compliance, and potential metabolic benefits including insulin sensitization.
Adult: One tablet once daily, preferably in the morning. Can be taken with or without food, but consistency is advised. Dose titration should be done based on individual response. Initiation with this FDC is recommended only if the patient's BP is likely to be controlled by all three components.
Note: Swallow the tablet whole with a glass of water. Do not crush or chew. Preferably taken in the morning to avoid nocturia due to Chlorthalidone. Maintain adequate fluid intake unless contraindicated (e.g., heart failure).
This combination exerts a multi-mechanistic, synergistic effect on blood pressure. Telmisartan selectively blocks the AT1 receptor, inhibiting angiotensin II's vasoconstrictive and aldosterone-secreting effects. Cilnidipine blocks L-type calcium channels on vascular smooth muscle (vasodilation) and N-type channels on sympathetic nerve terminals (inhibits norepinephrine release, reducing tachycardia and edema). Chlorthalidone inhibits Na+/Cl- cotransport in the distal convoluted tubule, promoting natriuresis and diuresis, reducing plasma volume and peripheral vascular resistance.
Pregnancy: CONTRANDICATED in 2nd and 3rd trimesters (Pregnancy Category D). Drugs that act on the RAS can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected. In 1st trimester, use only if clearly needed (Category C).
Driving: Caution advised, especially during initiation and dose adjustment, as dizziness, lightheadedness, or syncope may occur. Patients should not drive or operate machinery until they know how the medication affects them.
| Other Antihypertensives (Diuretics, Beta-blockers, ACEi) | Additive hypotensive effect. Risk of severe hypotension. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Reduce antihypertensive effect; increase risk of renal impairment and hyperkalemia (with Telmisartan). | Major |
| Potassium supplements / Potassium-sparing diuretics (Spironolactone, Amiloride) | Increased risk of hyperkalemia (with Telmisartan). | Major |
| Lithium | Chlorthalidone reduces renal clearance of Lithium, leading to toxicity. | Major |
| Digoxin | Hypokalemia from Chlorthalidone can predispose to Digoxin toxicity. | Moderate |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increase plasma levels of Cilnidipine, enhancing effects and side effects. | Moderate |
| CYP3A4 Inducers (Rifampicin, Phenytoin, Carbamazepine) | Decrease plasma levels of Cilnidipine, reducing efficacy. | Moderate |
| Allopurinol, Colchicine | Increased risk of hypersensitivity reactions with Chlorthalidone. | Moderate |
| Antidiabetic drugs (Insulin, Sulfonylureas) | Chlorthalidone may impair glucose tolerance, requiring dose adjustment. | Moderate |
| Corticosteroids | Increase risk of hypokalemia. | Moderate |
Same composition (Telmisartan (40mg) + Cilnidipine (10mg) + Chlorthalidone (6.25mg)), different brands: